RCS - Angle PLC - Publication demonstrates CTC profiling potential

AngleAnnouncement

17/10/2024 07:00

For best results when printing this announcement, please click on link below:
https://newsfile.refinitiv.com/getnewsfile/v1/story?guid=urn:newsml:reuters.com:20241017:nRSQ5055Ia&default-theme=true

RNS Number : 5055I  Angle PLC  17 October 2024

 For immediate release  17 October 2024

 

ANGLE plc ("the Company")

 

PUBLICATION DEMONSTRATES POTENTIAL FOR multi-marker CTC profiling IN EARLY
PROSTATE CANCER

 

Parsortix enriched CTCs detected at high rates in localised disease

 

Multi-marker profiling of CTCs could support development of targeted therapies
and help stratify patients in clinical trials

 

 

ANGLE plc (AIM:AGL OTCQX:ANPCY), a world-leading liquid biopsy company with
innovative circulating tumour cell (CTC) solutions for use in research, drug
development and clinical oncology, is pleased to announce the publication of
research investigating a panel of known prostate cancer gene transcripts in
CTCs, undertaken by the Comprehensive Cancer Center at the Medical University
of Vienna.

 

Researchers used the Parsortix(®) system to isolate and harvest CTCs from 38
localised and metastatic prostate cancer patients. CTCs were then analysed
using a range of molecular techniques which enabled multiple biomarkers to be
simultaneously analysed.

 

The study demonstrated the highly effective capture of CTCs using the
Parsortix system, with 67% of localised prostate cancer patients positive for
CTC biomarker(s) at baseline and 77% positive for CTC biomarker(s) after
treatment.

 

The findings indicated a strong correlation between specific CTC biomarkers
and clinical parameters, such as tumour grade and stage, suggesting that
multi-marker CTC analysis could aid in risk stratification for patients. This
adds to the body of evidence supporting ANGLE's large pharma strategy,
highlighting the potential to inform patient selection for clinical trials in
the development of targeted therapies.

 

Chief Scientific Officer, Karen Miller, commented:

"This study supports our pharma services business by demonstrating how a
Parsortix-enriched, CTC-based multi-marker approach can enhance the
development of targeted therapies and improve patient stratification in
clinical trials. This approach could ultimately lead to the development of new
classes of drugs which are more targeted and provide better outcomes for
patients, all of which may require a Parsortix-based companion diagnostic to
support regulatory clearance."

 

The research, published as a peer-reviewed publication in the journal Clinical
and Experimental Metastasis, is available online at
https://angleplc.com/resources/publications/.

 

For further information:

 

 ANGLE plc                               +44 (0) 1483 343434
 Andrew Newland, Chief Executive

 Ian Griffiths, Finance Director

 Berenberg (NOMAD and Broker)            +44 (0) 20 3207 7800

 Toby Flaux, Ciaran Walsh, Milo Bonser

 FTI Consulting

 Simon Conway, Ciara Martin              +44 (0) 203 727 1000

 Matthew Ventimiglia (US)                +1 (212) 850 5624

 

 

For Frequently Used Terms, please see the Company's website on
https://angleplc.com/investor-relations/glossary/
(https://angleplc.com/investor-relations/glossary/)

 

 

Notes for editors

 

About ANGLE plc

 

ANGLE is a world-leading liquid biopsy company with innovative circulating
tumour cell (CTC) solutions for use in research, drug development and clinical
oncology using a simple blood sample. ANGLE's FDA cleared and patent protected
CTC harvesting technology known as the Parsortix(®) PC1 System enables
complete downstream analysis of the sample including whole cell imaging and
proteomic analysis and full genomic and transcriptomic molecular analysis.

 

ANGLE's commercial businesses are focusing on diagnostic products and clinical
services. Products include the Parsortix system, associated consumables and
assays. The clinical services business is offered through ANGLE's
GCLP-compliant laboratories.  Services include custom made assay development
and clinical trial testing for pharma.

 

Over 100 peer-reviewed publications have demonstrated the performance of the
Parsortix system. For more information, visit www.angleplc.com
(http://www.angleplc.com)

 

Any reference to regulatory authorisations such as FDA clearance, CE marking
or UK MHRA registration shall be read in conjunction with the full intended
use of the product:

 

The Parsortix(®) PC1 system is an in vitro diagnostic device intended to
enrich circulating tumor cells (CTCs) from peripheral blood collected in
K(2)EDTA tubes from patients diagnosed with metastatic breast cancer. The
system employs a microfluidic chamber (a Parsortix cell separation cassette)
to capture cells of a certain size and deformability from the population of
cells present in blood. The cells retained in the cassette are harvested by
the Parsortix PC1 system for use in subsequent downstream assays. The end user
is responsible for the validation of any downstream assay. The standalone
device, as indicated, does not identify, enumerate or characterize CTCs and
cannot be used to make any diagnostic/prognostic claims for CTCs, including
monitoring indications or as an aid in any disease management and/or treatment
decisions.

 

All results reported in this announcement and any other products and services
are for research use only and not for use in diagnostic procedures.

This information is provided by Reach, the non-regulatory press release distribution service of RNS, part of the London Stock Exchange. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact
rns@lseg.com (mailto:rns@lseg.com)
 or visit
www.rns.com (http://www.rns.com/)
.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our
Privacy Policy (https://www.lseg.com/privacy-and-cookie-policy)
.   END  NRAKZMMGRVRGDZM